Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $0 | — | $-74.1M | $-1.06 | -14.0% | — | — |
| Q4 2025 Dec 2025 | $0 | — | $-69.4M | — | — | — | — |
| Q3 2025 Sep 2025 | $0 | — | $-65.0M | $-1.08 | -25.7% | — | — |
| Q2 2025 Jun 2025 | $0 | — | $-66.1M | $-1.11 | — | — | — |
| Q1 2025 Mar 2025 | $0 | — | $-55.3M | $-0.93 | — | — | — |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Is AbbVie’s $10.9 billion Apogee deal a bold immunology masterstroke, or an expensive bet on future growth? Maik Kemper Editor in Chief The acquisition of Apogee further builds…